null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Epcoritamab ELISA Kit (GXEL00117)

SKU GXEL00117
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms GEN3013, 2134641-34-0
€2,252
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Epcoritamab ELISA Kit

The Epcoritamab ELISA Kit (SKU: GXEL00117) is a quantitative sandwich ELISA designed for the accurate quantitative detection of Epcoritamab across Plasma, Serum. With a working range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit combines a simple protocol with dependable colorimetric read-out for confident quantification.

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.

Backed by Assay Genie quality control and technical support, this Epcoritamab ELISA Kit is an ideal tool for laboratories studying Epcoritamab. Order the Epcoritamab ELISA Kit from Assay Genie for dependable performance.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose